A Phase 1, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Determine the Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Healthy Adults With an Open-label Cohort of Patients With Huntington's Disease
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Dalzanemdor (Primary)
- Indications Huntington's disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sage Therapeutics
- 10 Dec 2019 According to a Sage Therapeutics media release, additional data from the Phase 1 open-label cohort study will be presented at a future congress in 2020.
- 10 Dec 2019 Results presented in a Sage Therapeutics Media Release.
- 15 Nov 2019 Status changed from recruiting to completed.